Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05608200 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Interventions: Lenvatinib (Drug), Lenvatinib plus sintilimab (Drug) to Lenvatinib plus TACE (Drug), Lenvatinib, sintilimab plus TACE (Drug)
    • Study description shortened, about 8 words
    • Study title shortened, about 5 words
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus TACE (Len-Sin-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced hepatocellular carcinoma (HCC).
Trial Details
NCT Number NCT05608200
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions
(from sponsor)		 Hepatocellular Carcinoma Non-resectable
Related terms Carcinoma, Hepatocellular
Enrollment 427 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov